Trevogrumab (anti-GDF8) with or without garetosmab (anti-activin A) for prevention of muscle loss during semaglutide-induced weight reduction in people with obesity (COURAGE): a two-part, phase 2, double-blind, placebo-controlled, randomised trial

The Lancet · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles